Home/Filings/4/0001209191-21-018526
4//SEC Filing

O'Grady Brendan P. 4

Accession 0001209191-21-018526

CIK 0000818686other

Filed

Mar 7, 7:00 PM ET

Accepted

Mar 8, 4:09 PM ET

Size

16.2 KB

Accession

0001209191-21-018526

Insider Transaction Report

Form 4
Period: 2021-03-04
O'Grady Brendan P.
EVP, North America Commercial
Transactions
  • Sale

    Ordinary Shares

    2021-03-04$10.57/sh7,469$78,91826,304.486 total
  • Exercise/Conversion

    Ordinary Shares

    2021-03-04+18,90533,773.486 total
  • Sale

    Ordinary Shares

    2021-03-05$10.54/sh11,436$120,58014,868.486 total
  • Sale

    Ordinary Shares

    2021-03-04$10.80/sh703$7,59214,868.486 total
  • Exercise/Conversion

    Restricted Share Units

    2021-03-0418,90537,811 total
    Ordinary Shares (18,905 underlying)
  • Award

    Restricted Share Units

    2021-03-05+109,315109,315 total
    Ordinary Shares (109,315 underlying)
Footnotes (8)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F3]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5100 to $10.6900, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5000 to $10.5775, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F7]Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.
  • [F8]Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025.

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001726533

Filing Metadata

Form type
4
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 4:09 PM ET
Size
16.2 KB